Gregory Pennock

605 total citations · 1 hit paper
4 papers, 441 citations indexed

About

Gregory Pennock is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Gregory Pennock has authored 4 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in Gregory Pennock's work include Vascular Tumors and Angiosarcomas (2 papers), Sarcoma Diagnosis and Treatment (2 papers) and Cancer Research and Treatments (1 paper). Gregory Pennock is often cited by papers focused on Vascular Tumors and Angiosarcomas (2 papers), Sarcoma Diagnosis and Treatment (2 papers) and Cancer Research and Treatments (1 paper). Gregory Pennock collaborates with scholars based in United States and United Kingdom. Gregory Pennock's co-authors include Damien M. Cronier, Gaurav Shah, Douglas Adkins, Robert Ilaria, Robin L. Jones, Jan Cosaert, William D. Tap, Mark Agulnik, Ilaria Conti and Michael B. Livingston and has published in prestigious journals such as The Lancet, Annals of Oncology and Gynecologic Oncology.

In The Last Decade

Gregory Pennock

4 papers receiving 433 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

2016 436 citations William D. Tap, Robin L. Jones et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory Pennock United States	3	334	277	113	72	39	4	441
Amy Qin United States	8	487 1.5×	472 1.7×	130 1.2×	99 1.4×	94 2.4×	12	720
Thibaud Valentin France	12	324 1.0×	202 0.7×	83 0.7×	107 1.5×	71 1.8×	38	505
Kelsey L. Watson United States	9	267 0.8×	111 0.4×	66 0.6×	77 1.1×	55 1.4×	10	403
Michał Wągrodzki Poland	14	395 1.2×	221 0.8×	69 0.6×	33 0.5×	52 1.3×	40	510
Ewa Chmielowska Poland	12	132 0.4×	251 0.9×	40 0.4×	119 1.7×	47 1.2×	44	468
Myrella Vlenterie Netherlands	11	407 1.2×	245 0.9×	124 1.1×	86 1.2×	47 1.2×	15	526
Jasmien Cornillie Belgium	14	330 1.0×	211 0.8×	84 0.7×	66 0.9×	73 1.9×	27	471
Chanchal Goswami India	11	297 0.9×	395 1.4×	22 0.2×	60 0.8×	65 1.7×	21	563
Ayşe Durnalı Türkiye	11	157 0.5×	173 0.6×	21 0.2×	63 0.9×	69 1.8×	25	340
Bernard Marquès France	12	556 1.7×	281 1.0×	157 1.4×	102 1.4×	53 1.4×	24	689

Countries citing papers authored by Gregory Pennock

Since Specialization

Citations

This map shows the geographic impact of Gregory Pennock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Pennock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Pennock more than expected).

Fields of papers citing papers by Gregory Pennock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory Pennock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Pennock. The network helps show where Gregory Pennock may publish in the future.

Co-authorship network of co-authors of Gregory Pennock

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory Pennock. A scholar is included among the top collaborators of Gregory Pennock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory Pennock. Gregory Pennock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Pérez‐Ollé, Raül, et al.. (2023). TIPS-18 TRIAL IN PROGRESS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B STUDY TO ASSESS THE SAFETY AND EFFICACY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGONUCLEOTIDE (IMV-001) TARGETING IGF-1R, IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology Advances. 5(Supplement_3). iii38–iii38. 1 indexed citations

2.

Richardson, Debra L., A. W. Tolcher, Timothy F. Burns, et al.. (2020). A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation. Gynecologic Oncology. 159. 52–52. 2 indexed citations

3.

Tap, William D., Robin L. Jones, Brian A. Van Tine, et al.. (2016). Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. The Lancet. 388(10043). 488–497. 436 indexed citations breakdown →

4.

Tap, William D., Robin L. Jones, Bartosz Chmielowski, et al.. (2016). A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor &agr; (pdgfr&agr;) monoclonal antibody, in advanced soft tissue sarcoma (sts). Annals of Oncology. 27. iv98–iv98. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact